Working… Menu

Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01901679
Recruitment Status : Completed
First Posted : July 17, 2013
Last Update Posted : November 6, 2014
Information provided by (Responsible Party):
Rockefeller University

Brief Summary:
The study plans to find out whether Celebrex may be potentially useful to decrease inflammation in fat tissues and thereby lower the production of substances such as estrogens that may increase the risk of developing breast cancer and lead to a poor outcome of the disease.

Condition or disease Intervention/treatment Phase
Obesity Drug: Celebrex Early Phase 1

Detailed Description:
This study seeks to examine how effective the celebrex may be in reducing inflammation, crown-like structures in fat tissue, the enzyme aromatase, PGE-M in the urine and estrogen in blood and urine. Volunteer subjects will be expected to stay in the hospital for about 2 weeks taking Celebrex for approximately 10 days while eating a diet similar to what they consumed before coming into the hospital for the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Pilot Study: Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women
Study Start Date : July 2013
Actual Primary Completion Date : August 2014
Actual Study Completion Date : August 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Celecoxib

Arm Intervention/treatment
Experimental: Celebrex
10 days treatment with Celebrex to evaluate reduction of PGE-M in urine
Drug: Celebrex
200 mg PO BID
Other Name: Celecoxib

Primary Outcome Measures :
  1. To determine whether oral administration of Celebrex to obese women will reduce the PGE-M in urine [ Time Frame: 10 days ]
    Study endpoint is a reduction in PGE-M in urine after treatment with celebrex

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Postmenopausal woman defined as: 24 consecutive months without a menstrual period and currently not taking any medication known to induce amenorrhea.
  • Serum estradiol < 20 pg/mL
  • Body Mass Index of 35-50
  • Stable weight defined as (+/- 5 %) of body weight for at least three months
  • 40-70 years of age
  • Fluent in English

Exclusion Criteria:

  • Known hypersensitivity to celecoxib or sulfonamides
  • Known peptic ulcer disease
  • Hypertension BP > 150/90 (on 2 occasions after resting)
  • Fasting blood glucose > 165 mg/dL
  • HIV positive
  • Screening creatinine > 2X upper limit of normal
  • Screening LFT results > 2x upper limit of normal
  • Smokers (or stopped < 3 months ago)
  • Framingham risk score > 15
  • Evidence of active coronary disease by history and/or EKG
  • Subjects who consume 25 grams of soy protein/day or more than 45 mg of isoflavones/day, for subjects who consume this amount of soy, they may stop for 14 days prior to admission
  • Currently taking NSAIDS, aspirin, (if > once a week, stopped <30 days ago).
  • Consuming > 3 servings of fish or seafood/week
  • Currently taking fish oil, omega-3 supplements or other herbal supplements that exceed GRAS (Generally Recognized as Safe) levels, (if currently taking fish oil/omega-3 supplements, there must be a 30 day washout period)
  • Current use of anti-coagulants
  • Currently taking any weight control medication
  • Currently taking thioridazine
  • Currently taking lithium
  • Currently taking any estrogen/progesterone hormones including vaginal cream, e-string, or vaginal tablets
  • Currently taking any medication that can alter fat stores as determined by the principal investigator
  • History of Inflammatory Bowel Disease or other chronic inflammatory disorders
  • History of any malignancy other than non-melanoma skin cancer in the past 5 years
  • History of any bleeding disorder
  • History of cardiovascular disease
  • Diagnosis of asthma
  • Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01901679

Layout table for location information
United States, New York
The Rockefeller University
New York, New York, United States, 10065
Sponsors and Collaborators
Rockefeller University
Layout table for investigator information
Principal Investigator: Peter Holt, MD Rockefeller University

Layout table for additonal information
Responsible Party: Rockefeller University Identifier: NCT01901679     History of Changes
Other Study ID Numbers: PHO-0807
First Posted: July 17, 2013    Key Record Dates
Last Update Posted: November 6, 2014
Last Verified: November 2014
Keywords provided by Rockefeller University:
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action